Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $80.15

Posted by Geri Gentry on Sep 18th, 2026

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $80.1538.

Several equities research analysts have issued reports on the company. Guggenheim raised their target price on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. HC Wainwright decreased their price target on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Raymond James Financial reiterated a “strong-buy” rating on shares of Vera Therapeutics in a report on Tuesday. JPMorgan Chase & Co. raised their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd.

Get Our Latest Analysis on Vera Therapeutics

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer directly owned 151,994 shares in the company, valued at $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 101,750 shares of company stock worth $3,992,300 over the last ninety days. Company insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VERA. Optimize Financial Inc raised its stake in Vera Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after acquiring an additional 256 shares in the last quarter. Intech Investment Management LLC boosted its stake in Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after acquiring an additional 424 shares in the last quarter. Arizona State Retirement System boosted its stake in Vera Therapeutics by 12.3% in the second quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock valued at $507,000 after acquiring an additional 1,295 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Vera Therapeutics by 8.8% during the first quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock worth $645,000 after purchasing an additional 1,300 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of Vera Therapeutics by 16.8% during the fourth quarter. ProShare Advisors LLC now owns 12,938 shares of the company’s stock worth $655,000 after purchasing an additional 1,864 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

Positive Sentiment: Phase 3 success supports approval hopes: Vera said TRUTAKNA met all primary and secondary endpoints in the ORIGIN 3 trial. The results showed sustained kidney protection over two years and a reduction in the decline of kidney function, strengthening the case for full approval in IgAN. Vera Therapeutics says TRUTAKNA met all Phase III endpoints
Positive Sentiment: Commercial opportunity is improving: The favorable ORIGIN 3 data could position TRUTAKNA for broader use in IgAN and intensify competition with other kidney-disease treatments, including products developed by Otsuka. Investors viewed the durable efficacy and kidney-function benefits as important differentiators. Vera’s strong Phase 3 IgAN data intensify kidney disease rivalry
Neutral Sentiment: Investors remain focused on execution: Positive trial results have increased expectations for regulatory approval and eventual commercialization, but some commentary remains cautious about approval timing, launch execution and competition. Vera Therapeutics: Why I’m sticking with Hold despite positive TRUTAKNA data
Negative Sentiment: CEO reduced his holdings: CEO Marshall Fordyce sold 18,500 shares for approximately $684,500, reducing his ownership by 7.29%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which limits its usefulness as a signal about management’s current outlook, but insider selling may still weigh modestly on sentiment. Vera Therapeutics CEO Form 4 filing

Vera Therapeutics Stock Up 7.9%

Shares of NASDAQ VERA opened at $34.27 on Friday. The company has a 50 day simple moving average of $34.43 and a 200-day simple moving average of $36.91. The company has a market capitalization of $2.47 billion, a P/E ratio of -5.85 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. Vera Therapeutics has a 1 year low of $23.05 and a 1 year high of $56.05.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same quarter in the previous year, the business posted ($1.20) EPS. On average, equities research analysts predict that Vera Therapeutics will post -6.44 earnings per share for the current year.

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.